Takeda Pharmaceutical (TAK) Competitors $13.73 -0.35 (-2.49%) Closing price 03:59 PM EasternExtended Trading$14.16 +0.43 (+3.13%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TAK vs. SNY, GSK, ARGX, ONC, INSM, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Takeda Pharmaceutical vs. Its Competitors Sanofi GSK argenex BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Is TAK or SNY a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 4.0%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Takeda Pharmaceutical pays out 183.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 38.5% of its earnings in the form of a dividend. Do insiders and institutionals have more ownership in TAK or SNY? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is TAK or SNY more profitable? Sanofi has a net margin of 21.47% compared to Takeda Pharmaceutical's net margin of 3.20%. Sanofi's return on equity of 16.86% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical3.20% 10.50% 5.10% Sanofi 21.47%16.86%9.63% Do analysts recommend TAK or SNY? Sanofi has a consensus target price of $62.67, suggesting a potential upside of 30.31%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Sanofi 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility & risk, TAK or SNY? Takeda Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Which has higher valuation and earnings, TAK or SNY? Sanofi has lower revenue, but higher earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.48T0.01$712.33M$0.3045.77Sanofi$44.46B2.66$6.02B$4.1611.56 Does the media prefer TAK or SNY? In the previous week, Sanofi had 24 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 28 mentions for Sanofi and 4 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.73 beat Takeda Pharmaceutical's score of 0.39 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 8 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive SummarySanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks. Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAK vs. The Competition Export to ExcelMetricTakeda PharmaceuticalMED IndustryMedical SectorNYSE ExchangeMarket Cap$43.69B$2.59B$6.01B$21.34BDividend Yield3.82%56.68%5.66%3.58%P/E Ratio45.7722.9285.3528.86Price / Sales0.01612.59582.9591.92Price / Cash4.50177.3038.3224.53Price / Book0.955.3712.724.51Net Income$712.33M$32.78M$3.30B$1.01B7 Day Performance-6.06%2.40%1.07%-3.37%1 Month Performance-10.17%10.27%7.61%-0.11%1 Year Performance-3.95%-0.18%79.71%11.75% Takeda Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAKTakeda Pharmaceutical2.3559 of 5 stars$13.73-2.5%N/A-1.2%$43.69B$4.48T45.7747,455SNYSanofi4.2709 of 5 stars$45.65+0.2%$62.67+37.3%-11.5%$112.09B$44.46B10.9782,878Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeGSKGSK2.0957 of 5 stars$41.08+3.1%$37.38-9.0%+7.9%$83.57B$40.10B19.0268,629Trending NewsDividend CutAnalyst ForecastARGXargenex3.6724 of 5 stars$719.04+1.0%$789.20+9.8%+54.6%$44.01B$2.25B36.871,599Analyst ForecastONCBeOne Medicines1.744 of 5 stars$332.83+2.1%$336.30+1.0%N/A$36.48B$3.81B-192.3911,000Analyst ForecastGap DownINSMInsmed3.1965 of 5 stars$141.65+3.4%$139.86-1.3%+135.0%$29.94B$363.71M-24.811,271Analyst ForecastBNTXBioNTech2.3722 of 5 stars$97.96-0.1%$134.56+37.4%-11.1%$23.55B$2.98B-61.226,772Positive NewsAnalyst ForecastTEVATeva Pharmaceutical Industries3.0481 of 5 stars$19.17+4.5%$25.14+31.2%+13.1%$21.99B$16.54B-119.8136,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.1917 of 5 stars$29.33+0.9%$40.00+36.4%+34.7%$18.82B$3.12B14.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.0539 of 5 stars$21.16+1.0%$31.29+47.9%+19.8%$15.72B$700K-20.95110Analyst ForecastASNDAscendis Pharma A/S3.0883 of 5 stars$191.60-0.2%$244.36+27.5%+66.1%$11.81B$393.54M-37.131,017News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies SNY Competitors GSK Competitors ARGX Competitors ONC Competitors INSM Competitors BNTX Competitors TEVA Competitors GMAB Competitors SMMT Competitors ASND Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TAK) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
